Drug intelligence / Profile preview

αC-targeting Adhirons

Development stage
Preclinical
Lead developer
University of Leeds
Modality
Recombinant Proteins and Enzymes, Peptides
Administration
Intravenous, Parenteral
01

Overview

αC-targeting Adhirons are small engineered protein binders (~12 kDa) based on a plant cystatin scaffold (previously known as Affimers) that selectively target the intrinsically disordered αC-region of fibrinogen with high affinity. Developed by researchers at the University of Leeds, these binders (including specific candidates αC-5, αC-8, and αC-45) modulate fibrin clot structure and stability. They exhibit dual effects on haemostasis and thrombosis: during clot formation, they delay clotting and decrease clot firmness (suggesting an antithrombotic effect), whereas once the clot is formed, they prolong clot stability and decelerate fibrinolysis. They are being investigated as potential therapeutic tools for modulating clot properties and reducing abnormal clot formation during thrombosis or bleeding complications.

Other names
conformational protein binders targeting fibrinogen alphaC-regionconformational protein binders targeting fibrinogen αC-regionfibrinogen alphaC-region targeting Adhironsfibrinogen αC-region targeting Adhironsfibrinogen-specific Adhironsfibrinogen-specific Affimers
02

Targets

Coagulation Factor XIIIFibrin (Factor Ia)PLG (Plasminogen)PLAT (Tissue-type plasminogen activator)FGA (Fibrinogen alpha chain)

Beyond the preview

Go deeper on αC-targeting Adhirons.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on αC-targeting Adhirons.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call